Integrative Therapies
As conversations on how to support veteran mental health evolve, there is growing interest in therapeutic approaches that extend into the integrative and holistic models of care. Integrative therapies—including mind-body practices, trauma-informed modalities, and plant-based treatments—are being explored in both clinical and supportive settings as potential tools for addressing PTSD, depression, and suicide risk.
Many of these therapies are not new, but are rooted in longstanding Indigenous and traditional practices that have supported healing for generations. Today, they are gaining increased recognition within Western research and can exist alongside mainstream approaches to mental health.
The Siotha Project is committed to staying updated on research and accessible resources in the evolving mental health landscape. While we do not provide or facilitate psychedelic-assisted therapies, we aim to serve as a trusted, grounded resource—helping veterans, families, and communities navigate information with clarity and care.
FEATURED CONTENT
The Siotha Project Blog Posts
Documentaries
-
In Waves and War – Follows veterans exploring alternative therapies, including ibogaine and 5-MeO-DMT, in clinical settings abroad.
Research & Organizations
-
MAPS (Multidisciplinary Association for Psychedelic Studies)
Research on MDMA-assisted therapy for PTSD
https://maps.org -
Johns Hopkins Center for Psychedelic & Consciousness Research
Ongoing studies on psilocybin and mental health
https://hopkinspsychedelic.org -
NYU Langone Center for Psychedelic Medicine
Clinical research on psychedelic-assisted therapies
https://med.nyu.edu/psychiatry/research/psychedelic-medicine -
U.S. Department of Veterans Affairs (VA) – Whole Health Program
Integrative approaches including mindfulness, movement, and wellness practices
https://www.va.gov/wholehealth/
Updates & Insights
-
April 2026 – A federal executive order directed the FDA and DEA to accelerate review of psychedelic compounds, with ibogaine named specifically, and committed at least $50 million toward research. The order is explicitly framed around veteran mental health, citing suicide and treatment-resistant PTSD.
-
May 2026 – Oklahoma Governor Kevin Stitt signed the Oklahoma Breakthrough Therapy Act (HB 3834) into law, authorizing the State Department of Health to contract with drug developers for state-funded ibogaine clinical trials targeting addiction, PTSD, and traumatic brain injury. The law also creates a state fund to support ongoing research.
-
May 2026 – Colorado passed legislation establishing a state-run ibogaine research pilot program through its Behavioral Health Administration.
-
July 2026 – The VA and HHS signed an agreement to coordinate research, clinician training, and data-sharing on psychedelic treatments for veterans' mental health.
-
MDMA-assisted therapy for PTSD remains under FDA review. The FDA declined approval in 2024 and requested an additional clinical trial; the VA has since launched its own MDMA trial for veterans with PTSD and co-occurring alcohol use disorder.
-
Oregon and Colorado continue to operate regulated psilocybin programs allowing supervised use in licensed settings.
Regional Update (2026):
Oklahoma has moved from early discussion to active policy: the Oklahoma Breakthrough Therapy Act now authorizes state-funded ibogaine research, with a framework for clinical trials expected to unfold over the coming months. Texas continues to lead the region in veteran-focused research funding, and Colorado has added a state-run ibogaine pilot program alongside its existing psilocybin framework. New Mexico remains in earlier stages of exploration. As with all of these developments, state authorization for research is not the same as public access — these remain tightly controlled clinical programs, not treatments available to the general public.